International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)

@article{Miyakis2006InternationalCS,
  title={International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)},
  author={S. Miyakis and M. Lockshin and T. Atsumi and D. Branch and R. Brey and R. Cervera and R. Derksen and P. D. de Groot and T. Koike and P. Meroni and G. Reber and Y. Shoenfeld and A. Tincani and P. Vlachoyiannopoulos and S. Krilis},
  journal={Journal of Thrombosis and Haemostasis},
  year={2006},
  volume={4}
}
Summary.  New clinical, laboratory and experimental insights, since the 1999 publication of the Sapporo preliminary classification criteria for antiphospholipid syndrome (APS), had been addressed at a workshop in Sydney, Australia, before the Eleventh International Congress on antiphospholipid antibodies. In this document, we appraise the existing evidence on clinical and laboratory features of APS addressed during the forum. Based on this, we propose amendments to the Sapporo criteria. We also… Expand

Paper Mentions

Interventional Clinical Trial
This treatment trial evaluates the addition of an anti-tumor necrosis factor-alpha drug, certolizumab, to usual treatment (a heparin agent and low-dose aspirin) in pregnant women… Expand
ConditionsAntiphospholipid Syndrome in Pregnancy, High Risk Pregnancy, Lupus Anticoagulant Disorder, (+1 more)
InterventionDrug
Interventional Clinical Trial
Patients with chronic rheumatic diseases (such as systemic lupus erythematosus [SLE], rheumatoid arthritis [RA], ankylosing spondylitis [AS], juvenile idiopathic arthritis [JIA… Expand
ConditionsAIDS, COVID-19, HIV Infections, (+3 more)
InterventionBiological
Interventional Clinical Trial
This study is designed to compare the safety and effectiveness of two blood thinners, apixaban and warfarin, for the prevention of blood clots in patients who have a higher risk… Expand
ConditionsAntiphospholipid Syndrome, Thrombosis
InterventionDrug
The Sydney Classification Criteria for Definite Antiphospholipid Syndrome
TLDR
The original antiphospholipid syndrome classification criteria (the Sapporo criteria) was published in 1999 and new clinical, laboratory, and experimental insights gained since then were addressed at the Eleventh International Congress on Antiphospholine Antibodies in Sydney, Australia, in 2006. Expand
15th International Congress on Antiphospholipid Antibodies Task Force on Antiphospholipid Syndrome Classification Report
TLDR
This chapter reviews the rationale for and methodology of the APS new classification criteria development efforts, and develops new evidence-based criteria that will better standardize patients for APS clinical trials and epidemiologic studies. Expand
Update on antiphospholipid syndrome.
  • M. Lockshin
  • Medicine
  • Bulletin of the NYU hospital for joint diseases
  • 2008
TLDR
This review addresses new clinical issues, mechanisms of action of antiphospholipid antibody, current therapies, and potential new therapies for multiple sclerosis-like disease and catastrophic syndrome. Expand
16th International congress on antiphospholipid antibodies task force report on clinical manifestations of antiphospholipid syndrome
TLDR
The task force concluded that APS does not have a uniform definition given the heterogeneity of the clinical presentations and different aPL profiles, and risk stratification strategies in aPL-positive patients can be useful in clinical practice. Expand
Antiphospholipid syndrome: the need for new international classification criteria
TLDR
There is a need to update the international APS classification taking into consideration the inclusion of new clinical criteria such as aPL-related nephropathy as well as new standardized antibody specificities with the adoption of a standardized scoring system that can stratify APS patients. Expand
Nonclassification Criteria Manifestations of the Antiphospholipid Syndrome
TLDR
The goal of this chapter is to highlight the significance of nonclassification criteria manifestations of APS based on clinical, observational, and experimental studies performed after the Sydney International workshop, in addition to recommendations issued by the International Congresses on antiphospholipid syndrome. Expand
Clinical relevance of the recent update of the classification criteria for definite antiphospholipid syndrome: an obstetric medicine clinic series of 107 patients
TLDR
A retrospective study of files of 107 women seen at an obstetric medicine clinic between 1 January 2000 and 31 December 2003, because of a positive antiphospholipid antibodies (aPL) assay, to illustrate the clinical relevance of these new criteria. Expand
Non-criteria Antiphospholipid Antibodies: a narrative review.
TLDR
Evidence is reviewed on the clinical associations and diagnostic value of the most commonly studied non-criteria antibodies, namely: antiphosphatidylethanolamine, anti-annexin A5,Anti-prothrombin complex, IgA anticardiolipin, and IgG anti-domain I of the β2 glycoprotein antibodies. Expand
Controversies and unresolved issues in antiphospholipid syndrome pathogenesis and management.
TLDR
Clinical questions remaining to be answered and debates concerning pathogenesis, diagnosis, and management are summarized. Expand
Livedo Reticularis as a Criterion for Antiphospholipid Syndrome
TLDR
Data is summarized that question or support the idea that many clinical symptoms (LR, valvular dysfunctions) or laboratory features (thrombocytopenia) should be considered as "minor criteria” for APS. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 194 REFERENCES
Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines
TLDR
Anticoagulation, corticosteroids, plasma exchange, intravenous gammaglobulins and, if associated with lupus flare, cyclophosphamide, are the most commonly used treatments for catastrophic APS patients. Expand
Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus.
TLDR
In 1992, Piette and colleagues suggested that the ACR revised criteria be reevaluated in light of the above discoveries, and the presence and clinical associations or antiphospholipid antibodies in patients with SLE was suggested. Expand
Guidelines On The Investigation and Management Of The Antiphospholipid Syndrome
TLDR
These revised guidelines on testing for the lupus anticoagulant have been prepared against this background and cover both clinical and laboratory aspects. Expand
Stroke and the antiphospholipid syndrome: consensus meeting Taormina 2002
TLDR
This work proposes a grading system that posits stroke to be definitely, likely or possibly associated with antiphospholipid antibodies (aPL), and cannot make strong recommendations as to optimal therapy, nor can it propose clear consensus treatment guidelines. Expand
Validation of the Sapporo criteria for antiphospholipid syndrome.
TLDR
The Sapporo criteria for APS compare favorably with the American College of Rheumatology criteria for SLE and are usable for clinical studies. Expand
Comparison of the primary and secondary antiphospholipid syndrome: a European Multicenter Study of 114 patients.
TLDR
Patients with APs plus SLE and PAPS have similar clinical profiles, although heart valve disease, hemolytic anemia, low C4 levels, and neutropenia seem to be more common in patients with APSplus SLE. Expand
Antiphospholipid antibodies
TLDR
It is hoped that the results of various controlled therapeutic trials in the APS will indicate better ways of managing these difficult manifestations and the pathogenesis and the optimal management of the syndrome are uncertain. Expand
Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients.
TLDR
An association with SLE, the patient's sex, and the patient’s age at disease onset can modify the disease expression and define specific subsets of APS. Expand
Cutaneous manifestations associated with antiphospholipid antibodies
TLDR
The purpose of this study was to determine the frequency of each cutaneous lesion, describing clinical features essential for diagnosis, in patients with Antiphospholipid Antibody Syndrome (AAS) attending Walter Cantídio University Hospital. Expand
The 1982 revised criteria for the classification of systemic lupus erythematosus.
TLDR
The 1971 preliminary criteria for the classification of systemic lupus erythematosus (SLE) were revised and updated to incorporate new immunologic knowledge and improve disease classification and showed gains in sensitivity and specificity. Expand
...
1
2
3
4
5
...